5.1 Endocrine System & Diabetes Management

5.1 Endocrine System & Diabetes Management

Endocrine disorders represent a significant proportion of acute and chronic medical-surgical admissions across hospitals in Abu Dhabi and the wider UAE. Clinical competence in managing glycemic crises, hormonal dysregulation, and electrolyte shifts is critical for the Department of Health (DOH) Registered Nurse examination. Nurses must integrate pathophysiology, pharmacokinetics, and rapid triage assessment to prevent life-threatening complications such as cerebral edema, fatal hypokalemic arrhythmias, and thyrotoxic collapse.

---

Diabetes Mellitus: Classification, Pathophysiology & Diagnostics

Diabetes mellitus comprises a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Understanding the pathophysiological divergence between the two primary classifications is essential for targeted clinical management.

Type 1 vs. Type 2 Diabetes Mellitus

• Type 1 Diabetes Mellitus (T1DM): Characterized by autoimmune destruction of insulin-producing pancreatic beta cells. Autoantibodies, such as anti-glutamic acid decarboxylase (anti-GAD) and islet cell antibodies, are markers of this autoimmune process. This leads to an absolute insulin deficiency. Patients are typically young, lean at diagnosis, and dependent on exogenous insulin for survival. Without exogenous insulin, uninhibited lipolysis and ketogenesis rapidly precipitate Diabetic Ketoacidosis (DKA).
• Type 2 Diabetes Mellitus (T2DM): Characterized by progressive peripheral insulin resistance accompanied by a relative, progressive secretory defect of beta cells and hepatic glucose overproduction. It is strongly linked to central adiposity, metabolic syndrome, sedentary lifestyle, and polygenic inheritance. Endogenous insulin production remains sufficient to suppress significant lipolysis and prevent ketosis under baseline conditions, but is insufficient to clear glucose loads, predisposing patients to Hyperosmolar Hyperglycemic State (HHS) during physiological stress.

Diagnostic Criteria for Diabetes Mellitus

According to ADA diagnostic criteria, diabetes is diagnosed by the thresholds below. Without unequivocal symptomatic hyperglycemia or a hyperglycemic crisis, confirm the diagnosis with two abnormal results: different tests may be obtained together, or a test may be repeated promptly. Confirmation does not always require waiting until another day.

---

Acute Diabetic Emergencies

1. Diabetic Ketoacidosis (DKA)

Diabetic Ketoacidosis is an acute, life-threatening metabolic emergency occurring predominantly in patients with Type 1 diabetes, triggered by omitted insulin therapy, acute infection (pneumonia, urinary tract infection, sepsis), myocardial infarction, stroke, trauma, or severe emotional stress.

Pathophysiological Sequence

1. Insulin Deprivation: In the absence of insulin, glucose cannot enter peripheral muscle and adipose tissues. The body perceives cellular starvation, prompting compensatory release of counter-regulatory stress hormones (glucagon, epinephrine, cortisol, and growth hormone).
2. Hepatic Gluconeogenesis & Lipolysis: Glucagon stimulates hepatic glycogenolysis and gluconeogenesis, elevating blood glucose. Concurrently, uninhibited lipolysis hydrolyzes triglycerides into free fatty acids (FFAs).
3. Ketogenesis & Acidosis: In the liver, FFAs undergo beta-oxidation into acidic ketone bodies: acetoacetate and beta-hydroxybutyrate. Accumulation of these organic acids depletes extracellular bicarbonate buffers, producing a high anion gap metabolic acidosis.
4. Osmotic Diuresis: Hyperglycemia exceeds the renal threshold (approx. 180 mg/dL), leading to glycosuria, osmotic diuresis, profound dehydration, and obligate urinary excretion of sodium, potassium, and magnesium.

Clinical Manifestations and Diagnostic Triad

• Diagnostic Triad: All three are required: glucose≥200 mg/dL or a prior history of diabetes; β-hydroxybutyrate≥3 mmol/L or urine ketones≥2+; and pH<7.3 and/or bicarbonate<18 mmol/L. DKA can occur with glucose below 200 mg/dL, particularly with SGLT2 inhibitors. An elevated anion gap supports the assessment but is not the preferred diagnostic or resolution measure.
• Physical Signs: Kussmaul respirations (rapid, deep breathing as respiratory compensation to blow off volatile carbonic acid as CO2), sweet "fruity" acetone breath odor, nausea, intractable vomiting, severe diffuse abdominal pain (mimicking acute surgical peritonitis), warm dry skin, sunken eyes, tachycardia, orthostatic hypotension, and altered mentation.

Evidence-Based Clinical Management Protocol

1. Intravenous Fluid Resuscitation (Primary Priority):

   • Initial Phase: In adults without cardiac or renal compromise, begin prescribed isotonic saline or balanced crystalloid at 500–1000 mL/hr for the first 2–4 hours. Reassess perfusion, fluid balance and electrolytes frequently; older adults and patients with heart or kidney failure need smaller, carefully reassessed volumes.
   • Subsequent Phase: Select fluid and rate from hydration, sodium and osmolality trends. A sodium rise during glucose correction is expected and is not by itself a reason to give hypotonic fluid.
   • Glycemic Transition: At glucose<250 mg/dL, add 5–10% dextrose to the saline infusion and usually reduce insulin to 0.05 units/kg/hr under the protocol. Dextrose prevents hypoglycemia while continued insulin clears ketones; it is not a mandatory switch to D5 half-normal saline.

2. Continuous Regular Insulin Infusion:

   • Regular U-100 insulin is the standard preparation in this DKA protocol. Other specific products, including NovoLog U-100 and Humalog U-100, are also approved for IV infusion under medical supervision. Use the prescribed product, dilution and route with close glucose and potassium monitoring; never substitute another concentration or formulation.
   • Initial infusion rate is 0.1 units/kg/hr (or an optional bolus of 0.1 units/kg followed by 0.1 units/kg/hr).
   • Target rate of glucose reduction is 50 to 75 mg/dL/hr. If glucose falls faster than 75 mg/dL/hr, reduce insulin or increase dextrose to prevent osmotic shock. If glucose fails to decrease by 10% in the first hour, re-evaluate hydration status and increase insulin infusion rate.
   • Continue insulin until plasma ketones are<0.6 mmol/L and (venous pH is≥7.3 or bicarbonate is≥18 mmol/L); glucose should ideally be<200 mg/dL. Do not use anion-gap closure alone to determine resolution. Give subcutaneous basal insulin 1–2 hours before stopping the infusion.

3. Potassium Monitoring and Replacement Safeguards:

   • Insulin stimulates the Na+/K+-ATPase pump, driving potassium rapidly from the extracellular space into intracellular compartments. Rehydration also dilutes serum potassium and increases urinary losses.
   • CRITICAL SAFETY THRESHOLD: Check potassium before insulin. If potassium is<3.5 mmol/L, delay insulin and give prescribed replacement (the adult consensus suggests 10 mmol/hr) until potassium is>3.5 mmol/L. Insulin can otherwise worsen hypokalemia and cause arrhythmias or respiratory muscle weakness.
   • Once potassium is safe for insulin but below 5.0 mmol/L, prescribed replacement is commonly 20–30 mmol per liter of IV fluid, targeting 4–5 mmol/L. Follow the patient-specific infusion and monitoring protocol.
   • If potassium is >5.0 mEq/L, hold potassium replacement but monitor levels every 2 hours; potassium will fall rapidly once insulin is initiated.

---

2. Hyperosmolar Hyperglycemic State (HHS)

Hyperosmolar Hyperglycemic State is a life-threatening acute metabolic decompensation occurring almost exclusively in older adult patients with Type 2 diabetes. It is frequently triggered by acute physiological stressors such as pneumonia, sepsis, myocardial infarction, stroke, or medications that impair glucose tolerance (corticosteroids, thiazide diuretics).

Key Pathophysiological Distinctions from DKA

• In HHS, minimal endogenous insulin secretion persists. This trace amount of circulating insulin is sufficient to inhibit adipose tissue hormone-sensitive lipase, thereby preventing significant lipolysis, ketone formation, and metabolic acidosis.
• However, insulin levels are insufficient to promote cellular glucose uptake or suppress hepatic gluconeogenesis.
• The onset is slow and insidious, evolving over days to weeks. Persistent glucosuria produces profound osmotic diuresis, causing massive fluid deficits (typically 8 to 10+ liters, equating to 100 to 200 mL/kg).
• Extremely high plasma osmolality draws water out of neurons in the central nervous system, leading to profound neurological depression (somnolence, confusion, hemiparesis, focal seizures, and coma). Mortality rates for HHS (10% to 20%) are substantially higher than for DKA (1% to 5%).

Diagnostic Criteria

All four are required:

• Plasma glucose≥600 mg/dL.
• Effective osmolality>300 mOsm/kg (2×Na [mmol/L]+glucose [mg/dL]/18) or total osmolality>320 mOsm/kg (includes urea).
• No significant ketonemia: β-hydroxybutyrate<3 mmol/L or urine ketones<2+.
• No acidosis by the diagnostic criteria: pH≥7.3 and bicarbonate≥15 mmol/L. Neurological impairment may occur but is not required for diagnosis. Assess for overlap with DKA.

Nursing Interventions

• Fluid Replacement: Start prescribed isotonic saline or balanced crystalloid and reassess circulation, lung sounds, fluid balance and osmolality. Avoid an automatic large-volume regimen in frail adults or heart/kidney failure. In HHS, limit osmolality decline to 3–8 mOsm/kg/hr, glucose decline to 90–120 mg/dL/hr and sodium decline to 10 mmol/L/24 hr.
• Insulin Administration: The adult consensus uses 0.05 units/kg/hr for HHS with β-hydroxybutyrate<3 mmol/L, pH≥7.3 and bicarbonate≥18 mmol/L; use the 0.1 units/kg/hr DKA/mixed-crisis pathway when significant ketonemia or acidosis is present. Add dextrose as glucose approaches the protocol threshold; continue controlled correction and electrolyte monitoring.
• Electrolyte Management: Strict potassium monitoring and replacement to prevent hypokalemic shifts during insulin therapy.

---

Comparison: Diabetic Ketoacidosis (DKA) vs. Hyperosmolar Hyperglycemic State (HHS)

The following clinical matrix summarizes the differentiating features, laboratory parameters, and resuscitation priorities tested on the DOH examination:

---

Hypoglycemia: Pathophysiology, Recognition & Emergency Protocols

Hypoglycemia is defined as a blood glucose concentration <70 mg/dL (<3.9 mmol/L). Level 2 hypoglycemia is glucose<54 mg/dL (<3.0 mmol/L). Level 3 (severe) hypoglycemia is altered mental or physical functioning requiring another person’s help for recovery, regardless of the glucose value. Both require prompt treatment.

Clinical Manifestations

Symptoms are categorized into two physiological phases:

1. Adrenergic / Autonomic Symptoms (Early Warning Signs): Triggered by autonomic sympathetic discharge and epinephrine release when blood glucose drops below ~65–70 mg/dL:

   • Diaphoresis (cool, clammy perspiration)
   • Tremors and fine shakiness
   • Tachycardia and palpitations
   • Extreme hunger (polyphagia)
   • Anxiety, nervousness, and pallor

   Warning

   Beta-blockers can mask warning signs such as tachycardia and tremor; autonomic neuropathy may also impair awareness. Sweating or neuroglycopenic symptoms such as confusion, dizziness and weakness may still occur. Check glucose promptly rather than relying on a particular symptom.

2. Neuroglycopenic Symptoms (Late / Dangerous Signs): Resulting from direct glucose starvation of cerebral neurons when blood glucose drops below ~50–55 mg/dL:

   • Frontal throbbing headache and lightheadedness
   • Inability to concentrate, slurred speech, and confusion
   • Visual disturbances (diplopia, blurred vision)
   • Emotional lability, aggression, or bizarre behavioral changes
   • Ataxia and loss of motor coordination
   • Generalized tonic-clonic seizures, coma, and irreversible brain damage

The Rule of 15 Management Algorithm (Conscious Patient)

For a conscious patient who is alert, oriented, and retains an intact gag and swallow reflex:

1. Administer 15 grams of fast-acting simple carbohydrate:
   • 120 mL (4 ounces / half cup) of unsweetened fruit juice or regular (non-diet) soda
   • 3 to 4 commercial glucose tablets
   • 1 tube of oral glucose gel
   • 1 tablespoon (15 mL) of granulated sugar or honey (Avoid complex carbohydrates or fats like chocolate, milk, or doughnuts initially, as fat retards gastric emptying and delays glucose absorption).
2. Wait 15 minutes and re-evaluate capillary blood glucose.
3. Assess Blood Glucose:
   • If blood glucose remains <70 mg/dL, repeat administration of another 15 grams of simple fast-acting carbohydrate.
   • Recheck blood glucose in 15 minutes.
4. Post-Stabilization Sustenance:
   • Once blood glucose is >=70 mg/dL, if the patient's next scheduled meal or snack is more than 1 hour away, provide a complex carbohydrate and protein snack (e.g., peanut butter with whole-wheat crackers, cheese sandwich, or milk) to sustain glycemic stability and prevent secondary rebound hypoglycemia.

Emergency Management (Unconscious or NPO Patient)

When a hypoglycemic patient presents with altered consciousness, stupor, seizures, or is strictly NPO:

• Intravenous Access Present:
  • Administer 25 to 50 mL of 50% Dextrose in Water (D50W) as a slow intravenous push over 2 to 5 minutes through a patent, large-bore peripheral or central IV line.
  • D50W is an extreme hypertonic vesicant; ensure blood aspiration confirms intravenous catheter patency prior to and during injection to prevent severe extravasation injury and tissue necrosis.
  • Recheck blood glucose in 15 minutes; maintain IV infusion of 5% or 10% dextrose if hypoglycemia recurs.
• Intravenous Access Absent:
  • Administer 1 mg of Glucagon via intramuscular (IM) or subcutaneous (SC) injection.
  • Glucagon mobilizes hepatic glycogen stores; it is ineffective in patients with depleted glycogen reserves (e.g., prolonged starvation, alcoholic liver disease).
  • CRITICAL PATIENT POSITIONING: Place the patient immediately into a lateral side-lying (recovery) position. Glucagon triggers intense nausea and vomiting as the patient regains consciousness; lateral positioning prevents aspiration of gastric contents.
  • Once consciousness returns and the patient can swallow safely, administer oral complex carbohydrates.

---

Thyroid Disorders: Hyperthyroidism & Hypothyroidism

The thyroid gland regulates systemic basal metabolic rate through the synthesis and secretion of thyroxine (T4) and triiodothyronine (T3), governed by pituitary Thyroid-Stimulating Hormone (TSH) under negative feedback control.

Hyperthyroidism and Thyrotoxicosis

Hyperthyroidism results from excessive circulating thyroid hormone levels. The most common etiology is Graves' disease, an autoimmune disorder where thyroid-stimulating immunoglobulins (TSI) bind to and continuously activate TSH receptors on thyroid follicular cells.

• Clinical Manifestations: Heat intolerance, warm flushed moist skin, fine resting tremors, sinus tachycardia, atrial fibrillation, hyperactive deep tendon reflexes, unintentional weight loss despite increased appetite, diarrhea, amenorrhea, emotional lability, and goiter with an audible vascular bruit. Graves'-specific signs include exophthalmos (proptosis) and pretibial myxedema (non-pitting orange-peel induration).
• Diagnostic Profile: Suppressed serum TSH (<0.01 mIU/L) with elevated free T4 and free T3.

Thyroid Storm (Thyrotoxic Crisis)

Thyroid storm is an acute, life-threatening hypermetabolic emergency triggered by surgical manipulation of the thyroid, infection, trauma, severe emotional stress, or abrupt cessation of antithyroid medications.

• Clinical Presentation: Extreme hyperpyrexia (temperatures frequently exceeding 40°C / 104°F), marked sinus tachycardia (>140 bpm), atrial fibrillation, congestive high-output heart failure, severe agitation, delirium, psychosis, nausea, vomiting, jaundice, and cardiovascular collapse.
• Emergency Nursing Interventions:
  1. Beta-Adrenergic Blockade: Administer IV propranolol to rapidly control tachycardia, agitation, and reduce peripheral conversion of T4 to T3.
  2. Antithyroid Medication: Administer high-dose Propylthiouracil (PTU) (typically 600–1000 mg loading dose orally or via nasogastric tube) or Methimazole to block hormone synthesis.
  3. Iodine Administration: Administer saturated solution of potassium iodide (SSKI) or Lugol's solution at least 1 hour AFTER antithyroid drug administration. Rationale: Giving iodine first provides substrate for new hormone synthesis; delaying iodine allows antithyroid drugs to block thyroid peroxidase first (Wolff-Chaikoff effect).
  4. Glucocorticoids: Administer IV hydrocortisone (100 mg q8h) to inhibit peripheral T4-to-T3 conversion and treat potential relative adrenal insufficiency.
  5. Cooling Measures: Apply hypothermia cooling blankets and administer acetaminophen for hyperthermia. AVOID ASPIRIN (salicylates) because salicylates displace thyroid hormones from thyroxine-binding globulin (TBG), dangerously increasing free circulating T3/T4.

Antithyroid Pharmacotherapy Comparison

• Propylthiouracil (PTU): Blocks thyroid peroxidase (inhibiting organification and coupling) AND inhibits peripheral conversion of T4 to T3. Short half-life (requires TID dosing). Agent of choice during the first trimester of pregnancy (lower risk of congenital teratogenicity) and in thyroid storm. Carries a Black Box Warning for severe, fulminant hepatotoxicity.
• Methimazole (Tapazole): Inhibits thyroid hormone synthesis without blocking peripheral conversion. Longer half-life (once-daily dosing). Agent of choice for non-pregnant adults and in the second and third trimesters of pregnancy. CRITICAL NURSING EDUCATION: Instruct patients to immediately report signs of infection, such as fever, chills, sore throat, or malaise. Methimazole can induce agranulocytosis (severe neutropenia). Obtain baseline blood tests as prescribed. Fever or sore throat requires withholding the drug, urgent clinician contact and a CBC with differential. Routine periodic CBCs are not universally mandated and cannot replace symptom-triggered assessment.

Post-Thyroidectomy Nursing Safeguards

Following subtotal or total thyroidectomy, prioritize monitoring for immediate life-threatening complications:

1. Airway Obstruction & Expanding Neck Hematoma: Keep an emergency tracheostomy tray, suction apparatus, and oxygen at the bedside. Assess for signs of tracheal compression: fullness in the neck, dressing tightness, respiratory distress, and audible inspiratory stridor (indicating laryngeal edema or bilateral recurrent laryngeal nerve damage). Position patient in semi-Fowler's with neck midline to minimize suture tension.
2. Hypocalcemia & Tetany (Inadvertent Parathyroidectomy): Accidental excision or devascularization of parathyroid glands leads to acute hypocalcemia within 24 to 72 hours. Assess for perioral tingling, digital numbness, muscle cramping, positive Chvostek's sign (facial muscle twitching elicited by tapping over facial nerve anterior to ear tragus), and positive Trousseau's sign (carpopedal spasm elicited by inflating blood pressure cuff 20 mmHg above systolic BP for 3 minutes). Maintain IV Calcium Gluconate 10% immediately available at the bedside for rapid emergency infusion.

---

Hypothyroidism and Myxedema Coma

Hypothyroidism is a clinical syndrome resulting from insufficient circulating thyroid hormones. The primary cause in non-endemic regions is Hashimoto's thyroiditis, an autoimmune destruction of thyroid parenchyma mediated by anti-thyroperoxidase (anti-TPO) antibodies. Other causes include radioiodine ablation, surgical thyroidectomy, and severe dietary iodine deficiency.

• Clinical Manifestations: Severe cold intolerance, extreme fatigue, lethargy, bradycardia, hypotension, non-pitting periorbital and generalized myxedema (mucopolysaccharide infiltration of dermis), cool dry pale skin, coarse brittle hair, constipation, menorrhagia, weight gain despite anorexia, slowed speech, and delayed "hung-up" deep tendon reflexes.
• Diagnostic Profile: Elevated serum TSH (typically >10 mIU/L) with decreased free T4.

Myxedema Coma

Myxedema coma is the end-stage, life-threatening decompensation of severe hypothyroidism. It is precipitated by systemic infection, cold exposure, trauma, stroke, heart failure, or administration of central nervous system depressants (sedatives, opioids, anesthetics).

• Cardinal Features: Severe hypothermia (core temperature often <32°C / 89.6°F), profound bradycardia, hypotension, hypoventilation leading to hypercapnia and respiratory acidosis, severe hyponatremia, hypoglycemia, and progressive coma.
• Emergency Interventions:
  1. Airway & Ventilation: Immediate endotracheal intubation and mechanical ventilation to manage hypercapnic respiratory failure.
  2. Intravenous Thyroid Replacement: Administer IV levothyroxine (T4), typically a 200–400 mcg loading dose as prescribed, with lower doses in older patients or those with coronary disease or arrhythmia. Monitor continuous ECG for myocardial ischemia or dysrhythmias.
  3. Adrenal Coverage: Administer IV Hydrocortisone (100 mg q8h) before or concurrently with levothyroxine. Accelerating metabolic rate with thyroid hormone in the presence of unaddressed secondary adrenal insufficiency can precipitate fatal acute adrenal crisis.
  4. Rewarming Protocol: Utilize passive external rewarming (warm blankets, elevated room temperature). AVOID active external rewarming (heating pads, warm baths) because rapid peripheral vasodilation induces profound hypotension and vascular collapse.

Levothyroxine (Synthroid) Patient Education

• Administration Timing: Take consistently once daily in the morning on an empty stomach with a full glass of water, at least 30 to 60 minutes before breakfast or morning caffeinated beverages, to optimize intestinal absorption.
• Drug Interactions: Separate levothyroxine administration by at least 4 hours from calcium carbonate, iron supplements (ferrous sulfate), aluminum/magnesium antacids, sucralfate, and cholestyramine, which bind thyroxine in the gastrointestinal tract and prevent systemic absorption.
• Lifelong Commitment: Emphasize that replacement therapy is lifelong; do not discontinue when feeling improved. Periodic TSH monitoring is required every 6 to 12 weeks during dose titration, and annually thereafter.
• Toxicity Recognition: Instruct patients to report signs of hyperthyroidism/overdose: chest pain, palpitations, rapid heart rate, insomnia, nervousness, or excessive weight loss.